[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494861":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":35,"locations":44,"responsibleParty":63,"collaborators":24,"id":66,"slug":24,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":24,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":24,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":47,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"HeO2 gas mixture, then Room air gas mixture","EXPERIMENTAL","Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive HeO2 first will then receive the room air gas mixture. At least 24 hours will separate each visit.",[13,14],"Other: HeO2 gas mixture","Other: Room air gas mixture",{"label":16,"type":10,"description":17,"interventionNames":18},"Room air gas mixture, then HeO2 gas mixture","Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive Room air first will then receive the HeO2 mixture. At least 24 hours will separate each visit.",[13,14],[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"HeO2 gas mixture","Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.",[9,16],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Room air gas mixture","Normal room air",[9,16],[30,33],{"name":31,"affiliation":5,"role":32},"Tony G Babb, Ph.D.","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":5,"role":32},"Bryce N Balmain, Ph.D.",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":24,"email":40},"Raksa B Moran, RN","CONTACT","214-345-6574","raksamoran@texashealth.org",{"name":42,"role":38,"phone":39,"phoneExt":24,"email":43},"Jessica N Alcala, RN","jessicaalcala@texashealth.org",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"UT Southwestern Medical Center","RECRUITING","Dallas","Texas","75390","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-96.80667,32.78306,{"lat":57,"lon":56},[60,62],{"name":37,"role":38,"phone":61,"phoneExt":24,"email":40},"2143456574",{"name":42,"role":38,"phone":61,"phoneExt":24,"email":43},{"type":32,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Bryce Balmain","Principal Investigator","100494861",false,"NCT05723679","Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF","Targeting Breathing Limitations to Improve Functional Outcomes in Heart Failure With Preserved Ejection Fraction (HFpEF)","Inclusion Criteria:\n\n* signs and symptoms of heart failure\n* an ejection fraction \\> 0.50;\n* objective evidence of diastolic dysfunction. elevated biomarkers (NT-proBNP \\>300 ng\u002Fdl) or HF hospitalization\n* healthy volunteers\n\nExclusion Criteria:\n\n* age \\\u003C 55 years\n* BMI \\> 50 kg\u002Fm2\n* Atrial fibrillation with poorly controlled heart rate\n* phosphodiesterase type 5 (PDE5) inhibitor use\n* severe valvular disease\n* severe Chronic obstructive pulmonary disease (COPD)\n* Chronic kidney disease (CKD) 4 or higher\n* any restriction of ambulation and mobility.",true,"ALL","55 Years","90 Years",{"count":77,"type":78},78,"ESTIMATED","INTERVENTIONAL",[81],"NA","The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance in patients with HFpEF.",[84,85],"Heart Failure With Preserved Ejection Fraction","Obesity",[87,88,89,90,91],"exertional dyspnea","exercise intolerance","HFpEF","breathing limitations","cardiopulmonary physiology","2026-05-01",{"date":94,"type":95},"2026-05-07","ACTUAL",{"date":97,"type":95},"2023-07-01",{"date":99,"type":78},"2029-06-30",{"name":5,"class":6},1]